Dr. Allen Kaplan graduated from Downstate Medical School (SUNY-Brooklyn) and completed his Residency in Medicine at Strong Memorial Hospital in Rochester, NY. From there he spent two years as a Clinical Fellow in the Arthritis and Rheumatism Branch of The National Institute of Arthritis and Metabolic Diseases followed by a Fellowship in Allergy and Clinical Immunology at the Harvard Medical School - Robert B. Brigham Hospital. He then returned to NIH as Head of the Allergic Diseases Section of NIAID where he remained for six years (1972-1978) and established the Allergic Diseases Center at NIH. Dr. Kaplan next moved to Stony Brook University where he was Head of the Division of Allergy, Rheumatology, and Clinical Immunology for 9 years, and was then named Chairman of the Department of Medicine. He remained at Stony Brook for 19 years and then came to The Medical University of South Carolina as Professor of Medicine. He is board certified in Internal Medicine, Allergy and Clinical Immunology, Rheumatology and Diagnostic Laboratory Immunology.
Dr. Kaplan was President of AAAAI in 1989, President of the Clinical Immunology Society in 1990, and President of The World Allergy Organization (WAO/IAACI) from 2000-2003. Author of over 300 publications, his major areas of interest are the mechanisms for production of bradykinin and its role in human disease, as well as the pathogenesis and treatment of urticaria and angioedema. He edited The Journal of The World Allergy Organization for five years, edited the textbook Allergy, is Co-Editor, with Dr. Malcolm Greaves, of a text entitled, Urticaria and Angioedema, and is Co-Editor of the two-volume textbook Allergy and Allergic Diseases.
Lisa A. Beck, MD
Lisa A. Beck, MD Professor of Dermatology and Medicine Director of Translational Research University of Rochester Medical Center Rochester, NY
Dr. Beck's laboratory focuses on understanding the interaction between skin barrier defects and the innate and adaptive immune system in subjects with atopic dermatitis, the most common inflammatory skin disorder. Her laboratory was the first to describe epidermal tight junction (TJ) defects in this disease. They continue to characterize these TJ defects at the molecular level and hope to determine whether these defects develop on a genetic, epigenetic or acquired basis. A number of therapeutic agents are being tested in vitro and in vivo for their ability to repair TJ defects. Her laboratory has also identified that several innate immune pathways including NOD2, TLR2 and 3 enhance epidermal TJ function. Her laboratory is also interested in understanding why subjects with atopic dermatitis are chronically colonized with bacteria, and more frequently infected with both bacteria and viruses. The working hypothesis is that AD subjects have an inadequate epidermal innate immune response to these cutaneous pathogens. Dr. Beck's clinical and laboratory work on atopic dermatitis has been supported by grants from the National Eczema Association, NIH/NIAID, NIH/NIAMS, Dermatology Foundation, and from biotechnology and pharmaceutical industries. She is a subcontractor on the NIH/NIAID funded Atopic Dermatitis Research Network (ADRN), which has amassed the largest registry of well-characterized subjects with Atopic Dermatitis in the US.
Marc A. Riedl, MD, MS
Marc A. Riedl, MD, MS Associate Professor of Medicine Clinical Director US HAEA Angioedema Center University of California – San Diego (UCSD) San Diego, CA
Marc A. Riedl, MD, MS, is Associate Professor of Medicine, Clinical Director of the US HAEA Angioedema Center, and Training Program Director for the Allergy & Immunology Fellowship Program at the University of California – San Diego (UCSD). He received his medical degree from the University of Chicago–Pritzker School of Medicine, completed a residency in internal medicine at Barnes-Jewish Hospital of Washington University in St. Louis, and a fellowship in clinical immunology and allergy at UCLA. Dr. Riedl received a Master of Science degree in clinical research and completed advanced training in clinical pharmacology at UCLA. He is board-certified in Allergy/Immunology, Internal Medicine, and Clinical Pharmacology. Dr. Riedl directs an active clinical research program at UCSD focusing on angioedema conditions, urticaria, and primary immunodeficiency with a strong professional interest in the development of novel therapeutics. He has published extensively in these areas and served on numerous editorial boards and scientific committees, as well as appointed expert panels for the FDA and NlH.
PHYSICIAN CONTINUING EDUCATION Accreditation Statement This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Allen P. Kaplan, MD, has affiliations with Genentech (Consulting); Dyax, Shire/ViroPharma (Speaking).
Marc A. Riedl, MD, MS, has no affiliations with commercial interests relative to the content to disclose.
Lisa A. Beck, MD, has affiliations with Array Biopharm, Celgene, Genentech, Leo Pharma, Medimmune, Novartis, Regeneron, and Sanofi (Consulting); Regeneron (Research); Wyeth (Stock).
Boris Rozenfeld, MD,has no affiliations with commercial interests relative to the content to disclose.
Nora Hartley, MLIS, has no affiliations with commercial interests relative to the content to disclose.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
DISCLOSURE OF UNLABELED USE This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: 0.5 hour Medium: Internet
FEE INFORMATION There is no fee for this educational activity.
COMMERCIAL SUPPORT This activity is supported by an independent educational grant from Genentech.
HOW TO RECEIVE CREDIT By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners and physician assistants are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page.
Read the learning objectives and faculty disclosures.
Participate in the activity.
Complete the post-test and activity evaluation.
Physicians, nurse practitioners and physician assistants who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 80% or higher on the post-test to receive credit for this activity.
All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above
For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above